Role of Matra Basti as Rasyana in jara janya Vikar Problems of Ageing

Abstract

ABSTRACT newline newlineObjectives of the study newlineGeneral objectives: newline1. To prevent or delay the onset of age related diseases in elderly patients/ people. newline2. To enable the aged to lead quality life there by to minimize pre death dependence. newlineSpecific objectives: newline1. To amalgamate the data on Gerontology from Ayurvedic literatures newline2. To prove whether Matravasti shows Multiple effects on different systems i.e., Rasayana effects in Jarajanya vikaras newline3. To substantiate the effects of Matravasti and Rasayana on clinical basis newlineMethodology of the study newlineEighty two patients - Men of age group 50 - 80 years; Women aged above 45 years or who have attained Menopause and lt75 years suffering from common problems of old age irrespective of sex, caste, religion etc. were registered for the study after taking informed consent. Out of which, 16 patients were dropped out. Remaining 66 were studied in detail. Recruitment of study subjects were carried out at MCD Ayurvedic Dispensary, Krishna Nagar, Delhi; PG dept. of Panchakarma, Madhav vilas hospital, Jaipur, MCD Ayurvedic Panchakarma Hospitals, Delhi. Matravasti was administered for 21 times with Balashwagandha lakshadi Tail on alternate days with a dosage 30 - 80ml accordingly. After completion of 21 days of Matravasti, all the patients were reviewed for successive 6 months. All the cases were assessed by considering different aspects like ADL, IADL, Emotional status (Geriatric depression scale), Cognitive status (3 Item recall minicog), Mobility, Gait and Balance Deficit (Performance oriented mobility assessment), Involuntary movements (Abnormal involuntary movement scale), Dyspnoea, Constipation, Pain (Brief pain inventory), Urinary incontinence, Dermatological manifestations, Sleep disturbances, Visual impairment, Hearing impairment and DHEA-S (Dehydroepiandrosterone sulfate). newline Outcome of the study newlineThe overall effect and maximum benefit observed was FAIR (25 % - 50 %) in 38 cases out of 66 patients. GOOD response (51 75 % response) in 26 cases and remaining 2 cases Best response (gt75%). An